Nuvectis director granted 35,000 restricted shares

Oliviero James F III reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Oliviero James F III reported acquisition or exercise transactions in this Form 4 filing.

Nuvectis Pharma director James F. Oliviero III received a grant of 35,000 shares of restricted common stock. These shares were awarded at no cash cost to him and are part of his equity compensation.

The restricted stock will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the company’s Board of Directors. Following this grant, he holds a total of 122,828 shares of Nuvectis Pharma common stock, including restricted shares.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider Oliviero James F III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	35,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 122,828 shares (Direct)

Footnotes (2)

1. F1. The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the Company's Board of Directors on such dates.
2. F2. Includes shares of restricted common stock.

Key Figures

Restricted stock grant: 35,000 shares Total holdings after grant: 122,828 shares Vesting period: 3 years +1 more

4 metrics

Restricted stock grant 35,000 shares Grant of restricted common stock to director on June 11, 2026

Total holdings after grant 122,828 shares Common stock beneficially owned following the award

Vesting period 3 years Restricted shares vest in equal annual installments beginning one year after grant

Grant price $0.0000 per share Indicates award granted at no cash cost to the director

Key Terms

restricted common stock, vest, Board of Directors, grant, award, or other acquisition

4 terms

restricted common stock financial

"The 35,000 shares of restricted common stock will vest in equal annual installments"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

vest financial

"will vest in equal annual installments over three years beginning on the first anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Board of Directors financial

"subject to Mr. Oliviero's continued service on the Company's Board of Directors on such dates"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuvectis Pharma (NVCT) director James F. Oliviero III receive in this Form 4?

He received a grant of 35,000 shares of restricted common stock. This equity award is part of his director compensation and was granted at no cash cost, increasing his total reported holdings in Nuvectis Pharma shares.

How do the 35,000 restricted Nuvectis Pharma (NVCT) shares vest for James F. Oliviero III?

The 35,000 restricted shares vest in equal annual installments over three years. Vesting begins on the first anniversary of the grant date and is conditioned on his continued service on Nuvectis Pharma’s Board of Directors on each vesting date.

What are James F. Oliviero III’s total Nuvectis Pharma (NVCT) holdings after this grant?

After the grant, he beneficially owns 122,828 shares of Nuvectis Pharma common stock. This total includes the newly granted restricted shares, as noted in the filing’s footnote describing that the position “includes shares of restricted common stock.”

Is the Nuvectis Pharma (NVCT) Form 4 transaction a market purchase or sale?

No, the transaction is a grant or award acquisition of shares. The Form 4 uses code “A” for a grant, award, or other acquisition, indicating this is compensation-related restricted stock, not an open-market buy or sell transaction.

What conditions apply to the restricted stock granted to the Nuvectis Pharma (NVCT) director?

The restricted stock will vest only if he remains on the company’s Board of Directors. Each of the three annual vesting installments requires his continued service on the Board on the relevant vesting date, according to the filing footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oliviero James F III

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.,

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NEW JERSEY 07024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		35,000(1)	A	$0	122,828(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the Company's Board of Directors on such dates.

2. Includes shares of restricted common stock.

	/s/ James F. Oliviero III	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)